Genprex has added multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Genentech’s Tecentriq to treat patients with extensive-stage small cell lung cancer. ES-SCLC is an aggressive form of lung cancer that is presently incurable. Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. Preclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq. The Acclaim-3 clinical trial is a Phase 1/2 study. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024. Genprex has received FDA Ophran Drug and Fast Track designations for the Acclaim-3 patient population.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX:
- Genprex initiated with a Buy at H.C. Wainwright
- Genprex announces $6.5M registered direct offering priced at the market
- Genprex to sell 1.54M shares at $4.215 in registered direct offering priced ATM
- Genprex to sell 1.54M shares at $4.215 per share
- Genprex receives Notice of Patent Grant for Korean patent
